Abbott Laboratories (ABT)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 113.10 |
| Open | 113.63 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 113.01 - 114.34 |
| 52-week range | 89.67 - 121.64 |
| Volume | |
| Avg. volume | 6,195,906 |
| Market cap | 198.105B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 35.92 |
| EPS (TTM) | 3.17 |
| Earnings date | 16 Oct 2024 - 21 Oct 2024 |
| Forward dividend & yield | 2.20 (1.93%) |
| Ex-dividend date | 15 Jul 2024 |
| 1y target est | 124.04 |
ZacksAbbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Investor's Business DailyHow Abbott Labs Is Leaning Into Obesity Treatment, And Taking On Dexcom
Abbott Laboratories launched its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.
ZacksIs It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
© 2024 Yahoo. All rights reserved.